What's in Shandong Suncadia Medicine Co., Ltd.'s pipeline?

Shandong Suncadia Medicine Co., Ltd. has 44 drugs in our index: 1 marketed, 0 filed, 8 in Phase 3, 7 in Phase 2, 28 in Phase 1.

Which companies overlap with Shandong Suncadia Medicine Co., Ltd.'s portfolio?

Top competitors by shared drug class: AstraZeneca, Pfizer, Novartis, GlaxoSmithKline, Hoffmann-La Roche.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/shandong-suncadia-medicine-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

Shandong Suncadia Medicine Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Shandong Suncadia Medicine Co., Ltd. pipeline: 1 marketed, 0 filed, 8 Phase 3, 7 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 8 Phase 3 7 Phase 2 28 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Everolimus Tablets	Everolimus Tablets	marketed	mTOR inhibitor	mTOR (mTORC1)	Oncology; Immunology
HRS-1780 Tablets	HRS-1780 Tablets	phase 3
Fulvestrant injection ;Dalpiciclib Isethionate	Fulvestrant injection ;Dalpiciclib Isethionate	phase 3	Selective estrogen receptor degrader (SERD) + CDK4/6 inhibitor combination	Estrogen receptor (ER) and cyclin-dependent kinases 4/6 (CDK4/6)	Oncology
HRS-8080 Tablets	HRS-8080 Tablets	phase 3
HRS-7535 tablet	HRS-7535 tablet	phase 3
HRS-8080 Tablet ; Dalpiciclib Isethionate	HRS-8080 Tablet ; Dalpiciclib Isethionate	phase 3	CDK4/6 inhibitor	CDK4/6	Oncology
HRS-7535 Tablets	HRS-7535 Tablets	phase 3
Tamoxifen Citrate Tablets	Tamoxifen Citrate Tablets	phase 3	Selective estrogen receptor modulator (SERM)	Estrogen receptor	Oncology
HRS-1893 Tablets	HRS-1893 Tablets	phase 3

Therapeutic area mix

Oncology · 3
Diabetes · 1
Oncology; Immunology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AstraZeneca · 3 shared drug classes
Pfizer · 3 shared drug classes
Novartis · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
Hoffmann-La Roche · 2 shared drug classes
National Taiwan University Hospital · 2 shared drug classes
Chong Kun Dang Pharmaceutical · 2 shared drug classes
H. Lee Moffitt Cancer Center and Research Institute · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Shandong Suncadia Medicine Co., Ltd.:

Cite this brief

Drug Landscape (2026). Shandong Suncadia Medicine Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shandong-suncadia-medicine-co-ltd. Accessed 2026-05-18.